Histogenics has enrolled 123 of the 245 patients required to complete enrollment of its ongoing NeoCart Phase 3 clinical trial.
Here are four takeaways:
1. The trial is being conducted under a special protocol assessment with the FDA.
2. The trial is designed to evaluate the safety and efficacy of NeoCart as a first-line therapy for full thickness knee cartilage defects in adults.
3. NeoCart is a cartilage-like, tissue engineered implant created from a patient’s own cartilage cells.
4. Histogenics is a regenerative medicine company focused on developing and commercializing products in the musculoskeletal market.